Metlife Inc (NYSE:MET) – Research analysts at FBR & Co issued their Q1 2018 earnings estimates for Metlife in a report issued on Thursday. FBR & Co analyst R. Binner expects that the financial services provider will post earnings of $1.44 per share for the quarter. FBR & Co has a “Outperform” rating and a $58.00 price objective on the stock. FBR & Co also issued estimates for Metlife’s Q2 2018 earnings at $1.43 EPS, Q3 2018 earnings at $1.47 EPS, Q4 2018 earnings at $1.42 EPS and FY2018 earnings at $5.75 EPS.

Metlife (NYSE:MET) last posted its quarterly earnings data on Wednesday, May 3rd. The financial services provider reported $1.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.19. Metlife had a net margin of 1.30% and a return on equity of 7.17%. The company had revenue of $16.27 billion during the quarter, compared to analysts’ expectations of $17.02 billion. During the same period in the prior year, the company posted $1.20 earnings per share. Metlife’s revenue for the quarter was down 11.7% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: “Metlife Inc Forecasted to Post Q1 2018 Earnings of $1.44 Per Share (MET)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/06/18/metlife-inc-forecasted-to-post-q1-2018-earnings-of-1-44-per-share-met-updated-updated.html.

Earnings History and Estimates for Metlife (NYSE:MET)

A number of other equities research analysts have also commented on MET. Deutsche Bank AG reiterated a “buy” rating and set a $65.00 price target on shares of Metlife in a report on Sunday, February 5th. Royal Bank of Canada reiterated a “buy” rating and set a $61.00 price target on shares of Metlife in a report on Monday, February 6th. Zacks Investment Research upgraded shares of Metlife from a “sell” rating to a “hold” rating in a report on Wednesday, February 15th. Citigroup Inc reiterated a “focus list” rating on shares of Metlife in a report on Tuesday, February 21st. Finally, TheStreet lowered shares of Metlife from a “b-” rating to a “c” rating in a report on Friday, February 24th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $55.94.

Shares of Metlife (NYSE:MET) opened at 51.05 on Friday. Metlife has a 52-week low of $36.17 and a 52-week high of $58.09. The stock’s 50 day moving average is $51.64 and its 200 day moving average is $53.33. The firm’s market capitalization is $54.93 billion.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. First Trust Advisors LP raised its position in shares of Metlife by 15.7% in the third quarter. First Trust Advisors LP now owns 1,107,393 shares of the financial services provider’s stock valued at $49,201,000 after buying an additional 149,958 shares during the period. Quantitative Investment Management LLC increased its stake in Metlife by 189.9% in the third quarter. Quantitative Investment Management LLC now owns 142,900 shares of the financial services provider’s stock worth $6,349,000 after buying an additional 93,600 shares in the last quarter. Aperio Group LLC increased its stake in Metlife by 11.7% in the third quarter. Aperio Group LLC now owns 464,116 shares of the financial services provider’s stock worth $20,621,000 after buying an additional 48,699 shares in the last quarter. Klingenstein Fields & Co. LLC increased its stake in Metlife by 7.1% in the third quarter. Klingenstein Fields & Co. LLC now owns 363,185 shares of the financial services provider’s stock worth $16,136,000 after buying an additional 24,171 shares in the last quarter. Finally, Bank of The Ozarks increased its stake in Metlife by 1.8% in the third quarter. Bank of The Ozarks now owns 19,328 shares of the financial services provider’s stock worth $859,000 after buying an additional 347 shares in the last quarter. Institutional investors and hedge funds own 74.92% of the company’s stock.

In related news, Director James M. Kilts acquired 17,205 shares of the firm’s stock in a transaction on Wednesday, March 22nd. The stock was acquired at an average cost of $51.13 per share, for a total transaction of $879,691.65. Following the acquisition, the director now owns 59,443 shares of the company’s stock, valued at $3,039,320.59. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James M. Kilts acquired 2,795 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was bought at an average price of $54.17 per share, with a total value of $151,405.15. Following the completion of the acquisition, the director now directly owns 41,951 shares in the company, valued at approximately $2,272,485.67. The disclosure for this purchase can be found here. 0.27% of the stock is currently owned by corporate insiders.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 13th. Shareholders of record on Monday, May 8th will be issued a $0.40 dividend. The ex-dividend date is Thursday, May 4th. This represents a $1.60 annualized dividend and a yield of 3.13%. Metlife’s dividend payout ratio (DPR) is presently 262.30%.

Metlife Company Profile

MetLife, Inc is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include U.S.; Asia; Latin America; Europe, the Middle East and Africa (EMEA); MetLife Holdings; Brighthouse Financial, and Corporate & Other. Its U.S. segment is organized into Group Benefits, Retirement and Income Solutions and Property & Casualty businesses.

12 Month Chart for NYSE:MET

Receive News & Stock Ratings for Metlife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife Inc and related stocks with our FREE daily email newsletter.